Author Archives: achicotel

About achicotel

Anthony Chicotel is a staff attorney for CANHR. His areas of expertise include the rights of long-term care residents, nursing home litigation, health care decision-making, and conservatorships.

Selling Out: Johnson and Johnson and the Shameful Story of Risperdal

Reporter Steven Brill’s stellar 15 chapter “docu-serial” about Johnson and Johnson’s illegal, immoral, yet highly successful campaign to achieve blockbuster status for the antipsychotic drug Risperdal is now available on the Huffington Post.  The series is a remarkable tale of greed, … Continue reading

Share

Don’t Forget Those in Assisted Living

“Galvanized by the mounting evidence, the Centers for Medicare and Medicaid Services (CMS) launched a national initiative that reduced antipsychotic medication use more than 20% by December 2014. In contrast, there is a conspicuous absence of visible action regarding antipsychotic … Continue reading

Share

Can Nursing Homes Get 300,000 Dementia Patients off Deadly Antipsychotics?

In another feature to its excellent reporting on failures in nursing home care, Al Jazeera’s “America Tonight” program examined more problematic elements of drugging dementia last week. The latest story focuses on one California woman’s experience of being drugged into … Continue reading

Share

Cough Suppressant – The New Choice in Chemical Restraint?

For years, pharmaceutical company Avanir has been steadily drumming up support for use of its drug Nuedexta as a “treatment” for dementia related “symptoms.” The September edition of an American Medical Director’s Association newsletter recently featured a story touting the … Continue reading

Share

Measuring Quality Through Antipsychotic Use (or Non-Use)

Since December 2008, the federal government’s Centers for Medicare and Medicaid Services (CMS) has used a five-star quality ratings system as a measure of the quality of care provided in nursing homes to include in its consumer-oriented Nursing Home Compare … Continue reading

Share

Care-Plan-In-a-Can Is Not Acceptable Dementia Care

In an earlier post, we talked about the CMS “focused surveys” to examine the dementia care provided at a handful of nursing homes in a few states, including California. The survey teams found many examples of poor dementia care by … Continue reading

Share

CMS Antipsychotic Surveys Reveal Drugging Misuse. Future Efforts Left to Volunteers

Back in March, CMS issued a report with the results of its focused dementia care survey pilot. The pilot project involved CMS and state regulators teaming up to “more thoroughly examine the process for prescribing antipsychotic medication and assess compliance … Continue reading

Share

A $3.8 Million Bummer

Last year, we heaped praise on the U.S. Department of Justice for filing a False Claims Act against two Watsonville, California nursing homes that had dangerously drugged multiple residents over several years. This week, the Department announced the case had … Continue reading

Share

No Surprises Why Nursing Homes Give Antipsychotics

Alice Bonner, one of the architects of CMS’s national initiative to reduce antipsychotic use in nursing homes, has co-authored a study investigating why antipsychotics are so often used on nursing home residents with dementia. The study, published in the Feb. … Continue reading

Share

What We Hope Comes from the New GAO Report on Antipsychotics

A GAO report released this week has found nationwide overuse of antipsychotic drugs for people with dementia. The focus of the report was explicitly outside of nursing homes. While 1 in 3 nursing home residents with dementia are given typically … Continue reading

Share